Nektar Therapeutics (NASDAQ: NKTR) stock closed at $20.92 on 8/9/19 after a major decline of -29.3%. Moreover, exceptionally high trading volume at 1161% of normal accompanied the decline. The stock has been weak relative to the market over the last nine months and has declined -32.9% during the last week.
Current PriceTarget Research Rating
NKTR is expected to continue to be a major Value Eraser reflecting capital returns that are forecasted to fall short of the cost of capital.
Nektar Therapeutics has a current Value Trend Rating of F (Lowest Rating). The Value Trend Rating reflects consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Nektar Therapeutics has a poor Appreciation Score of 20 and a very low Power Rating of 14, producing the Lowest Value Trend Rating.
In light of this highly negative price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.